 CARSON CITY, Nev., Nov. 15, 2022 GLOBE NEWSWIRE -- BioVie Inc., NASDAQ: BIVI BioVie or the Company a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimers Disease AD were accepted for presentation at the 2022 Clinical Trials on Alzheimers Disease CTAD Annual Meeting, to be held November 29-December 2, 2022 in San Francisco, CA. 